Diabetes Care: The relationship between statin therapy and the risk of multiple neuropathy in people with type 2 diabetes.

Statins can reduce the risk of diabetic multiple neuropathy (DPN) by reducing fat and anti-inflammatory effects, but statins are also associated with neurotoxicity.
a recent study published in Diabetes Care, an authoritative journal in the field of diabetes, researchers aim to assess whether statin therapy affects the risk of DPN.
identified all people with type 2 diabetes in Denmark between 2002 and 2016.
new users of statins start taking statins between 180 and 180 days before the diagnosis of diabetes, while current users start taking statins before that time.
180 days after the diagnosis of diabetes, patients are followed up with an event using a validated hospital diagnostic code.
Cox Proportional Risk Analysis is used to calculate the adjusted risk ratio (aHRs) for the DPN.
the study included 59,255 (23%) new users of statins, 75,528 (29%) current users and 124,842 (48%) non-users.
the mid-level follow-up time was 6.2 years (3.4-9.6 quarter spacing).
rate of DPN events per thousand people is similar for new users (4.0 (4.0) 95% CI is 3.8-4.2), current users (3.8 (3.6-3.9)) and non-users (3.8 (3.7-4.0)).
compared to non-statin users, the aHR of the new user's DPN is 1.05 (0.98-1.11) and the current user is 0.97 (0.91-1.04).
in the first year, the risk of DPN for new users increased slightly (1.31 (1.12-1.53).
results were similar in the analysis of treatment and tendency score matching, and additional adjustments were made to blood lipid levels prior to treatment.
, although the small risk of acute injury cannot be ruled out, statin therapy is unlikely to increase or reduce the risk of DPN in people with type 2 diabetes.
.